Mark M. Yore

3.8k citations

21 papers · 3.1k indexed · 2 hit papers · h-index 19

Toxicology top 1%
- Bioactive Compounds and Antitumor Agents 3
Biochemistry top 2%
- Antioxidant Activity and Oxidative Stress 4
Biochemistry top 2%
- Antioxidant Activity and Oxidative Stress 4
Molecular Biology top 5%
- Genomics, phytochemicals, and oxidative stress 9
- Natural product bioactivities and synthesis 6
- Retinoids in leukemia and cellular processes 6
- Glutathione Transferases and Polymorphisms 3
- Plant biochemistry and biosynthesis 2
Physiology top 5%
Genetics
- Estrogen and related hormone effects 3

Co-authors: Michael B. Sporn Karen T. Liby Gordon W. Gribble Barbara B. Kahn Pedro M. Moraes‐Vieira Ismail Syed Tadashi Honda Pratik Aryal
Cited by: Toxicology Biochemistry
Journals: Cancer Research (4 papers)Journal of Biological Chemistry (3 papers)Cell Metabolism (2 papers)
Partner nations: United States United Kingdom Sweden

In The Last Decade

Mark M. Yore

21 papers receiving 3.0k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Mark M. Yore

Since Specialization

Citations

This map shows the geographic impact of Mark M. Yore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Yore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Yore more than expected).

Fields of papers citing papers by Mark M. Yore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark M. Yore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Yore. The network helps show where Mark M. Yore may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark M. Yore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark M. Yore Line = papers co-authored together Mark M. Yore links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Retinol binding protein 4 primes the NLRP3 inflammasome by signaling through Toll-like receptors 2 and 4 Proceedings of the National Academy of Sciences ·Pedro M. Moraes‐Vieira,Mark M. Yore,Alexandra Sontheimer-Phelps,Ângela Castoldi,Julie Norseen,Pratik Aryal,Kotryna Simonyté Sjödin,Barbara B. Kahn	2020	66
2	Palmitic Acid Hydroxystearic Acids Activate GPR40, Which Is Involved in Their Beneficial Effects on Glucose Homeostasis Cell Metabolism ·Ismail Syed,Jennifer Lee,Pedro M. Moraes‐Vieira,Cynthia J. Donaldson,Alexandra Sontheimer-Phelps,Pratik Aryal,Kerry Wellenstein,Matthew J. Kolar,Gavin J. Neil,Dionicio Siegel,Jacek Mokrosiński,I. Sadaf Farooqi,Rosane Lopes Collares,Mark M. Yore,Odile D. Peroni,Alan Saghatelian,Barbara B. Kahn	2018	150
3	Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory Effectsbreakdown → Cell ·Mark M. Yore,Ismail Syed,Pedro M. Moraes‐Vieira,Tejia Zhang,Mark A. Herman,Edwin A. Homan,Rajesh T. Patel,Jennifer Lee,Shili Chen,Odile D. Peroni,V. V. Zasetsky,Ann Hammarstedt,Ulf Smith,Timothy E. McGraw,Alan Saghatelian,Barbara B. Kahn	2014	648
4	RBP4 Activates Antigen-Presenting Cells, Leading to Adipose Tissue Inflammation and Systemic Insulin Resistance Cell Metabolism ·Pedro M. Moraes‐Vieira,Mark M. Yore,Anna Ivanovna Chetverikova,Ismail Syed,Pratik Aryal,Barbara B. Kahn	2014	222
5	Retinol-Binding Protein 4 Inhibits Insulin Signaling in Adipocytes by Inducing Proinflammatory Cytokines in Macrophages through a c-Jun N-Terminal Kinase- and Toll-Like Receptor 4-Dependent and Retinol-Independent Mechanism Molecular and Cellular Biology ·Julie Norseen,Tetsuya Hosooka,Ann Hammarstedt,Mark M. Yore,Shashi Kant,Pratik Aryal,Urban A. Kiernan,David Phillips,Hiroshi Maruyama,Bettina J. Kraus,Anny Usheva,Roger J. Davis,Ulf Smith,Barbara B. Kahn	2012	211
6	Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR PLoS ONE ·Mark M. Yore,Arminja N. Kettenbach,Michael B. Sporn,Scott A. Gerber,Karen T. Liby	2011	83
7	Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice Cancer Prevention Research ·Karen T. Liby,Renee Risingsong,Darlene B. Royce,Charlotte R. Williams,Tian Ma,Mark M. Yore,Michael B. Sporn	2009	50
8	Prevention and Treatment of Experimental Estrogen Receptor–Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268 Clinical Cancer Research ·Karen T. Liby,Renee Risingsong,Darlene B. Royce,Charlotte R. Williams,Mark M. Yore,Tadashi Honda,Gordon W. Gribble,William W. Lamph,Nicola Vannini,Ilaria Sogno,Adriana Albini,Michael B. Sporn	2008	66
9	A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin Cancer Research ·Karen T. Liby,Mark M. Yore,Bill D. Roebuck,Karen J. Baumgartner,Tadashi Honda,Chitra Sundararajan,Hidenori Yoshizawa,Gordon W. Gribble,Charlotte R. Williams,Renee Risingsong,Darlene B. Royce,Albena T. Dinkova‐Kostova,Katherine K. Stephenson,Patricia A. Egner,Melinda S. Yates,John D. Groopman,Thomas W. Kensler,Michael B. Sporn	2008	42
10	The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis Molecular Cancer Therapeutics ·Karen T. Liby,Candice C. Black,Darlene B. Royce,Charlotte R. Williams,Renee Risingsong,Mark M. Yore,Xi Liu,Tadashi Honda,Gordon W. Gribble,William W. Lamph,Thomas A. Sporn,Ethan Dmitrovsky,Michael B. Sporn	2008	31
11	Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancerbreakdown → Nature reviews. Cancer ·Karen T. Liby,Mark M. Yore,Michael B. Sporn	2007	529
12	Platforms and networks in triterpenoid pharmacology Drug Development Research ·Michael B. Sporn,Karen T. Liby,Mark M. Yore,Nanjoo Suh,Adriana Albini,Tadashi Honda,Chitra Sundararajan,Gordon W. Gribble	2007	33
13	The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice Cancer Research ·Karen T. Liby,Darlene B. Royce,Charlotte R. Williams,Renee Risingsong,Mark M. Yore,Tadashi Honda,Gordon W. Gribble,Ethan Dmitrovsky,Thomas A. Sporn,Michael B. Sporn	2007	124
14	The synthetic triterpenoid, CDDO-Imidazolide blocks nuclear factor-κB activation through direct inhibition of IκB kinase-beta. Cancer Epidemiology and Prevention Biomarkers ·Mark M. Yore,Karen T. Liby,Tadashi Honda,D. D. Drowley,Michael B. Sporn	2006	4
15	Smoothened Regulates Activator and Repressor Functions of Hedgehog Signaling via Two Distinct Mechanisms Journal of Biological Chemistry ·Stacey K. Ogden,David Casso,Manuel Ascano,Mark M. Yore,Thomas B. Kornberg,David J. Robbins	2006	16
16	The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β Molecular Cancer Therapeutics ·Mark M. Yore,Karen T. Liby,Tadashi Honda,Gordon W. Gribble,Michael B. Sporn	2006	101
17	Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Triterpenoid 1-[2-Cyano-3-,12-Dioxooleana-1,9(11)-Dien-28-Oyl]Imidazole Cancer Research ·Melinda S. Yates,Mi-Kyoung Kwak,Patricia A. Egner,John D. Groopman,Sridevi Bodreddigari,Thomas R. Sutter,Karen J. Baumgartner,Bill D. Roebuck,Karen T. Liby,Mark M. Yore,Tadashi Honda,Gordon W. Gribble,Michael B. Sporn,Thomas W. Kensler	2006	165
18	Limiting Effects of RIP140 in Estrogen Signaling Journal of Biological Chemistry ·Eboni Marshall Turman,Mark M. Yore,雄大西,Michael J. Spinella	2005	25
19	The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling Cancer Research ·Karen T. Liby,Thomas Hock,Mark M. Yore,Nanjoo Suh,Andrew E. Place,Renee Risingsong,Charlotte R. Williams,Darlene B. Royce,Tadashi Honda,Yukiko Honda,Gordon W. Gribble,Nathalie Hill‐Kapturczak,Anupam Agarwal,Michael B. Sporn	2005	239
20	Negative Feedback at the Level of Nuclear Receptor Coregulation Journal of Biological Chemistry ·Eboni Marshall Turman,Mark M. Yore,RICHARD S. PARKINSON,Angelina V. Vaseva,R. L. Stafford,Sarah J. Freemantle,Michael J. Spinella	2003	28

About Mark M. Yore

Mark M. Yore is a scholar working on Toxicology, Biochemistry and Molecular Biology, having authored 21 papers that have together received 3.1k indexed citations. Recurring topics across this work include Genomics, phytochemicals, and oxidative stress (9 papers), Natural product bioactivities and synthesis (6 papers), Retinoids in leukemia and cellular processes (6 papers), Antioxidant Activity and Oxidative Stress (4 papers), Bioactive Compounds and Antitumor Agents (3 papers), Glutathione Transferases and Polymorphisms (3 papers), Estrogen and related hormone effects (3 papers) and Plant biochemistry and biosynthesis (2 papers). The work is most often cited by research in Toxicology (171 citations), Biochemistry (241 citations) and Biochemistry (255 citations). Mark M. Yore has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Barbara B. Kahn, Pedro M. Moraes‐Vieira, Ismail Syed, Tadashi Honda, Pratik Aryal, Ann Hammarstedt and Ulf Smith. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Cell Metabolism, Molecular Cancer Therapeutics and Nature reviews. Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact